Coronary Sinus Reducer an Option for Intractable Angina?
A coronary sinus reducer met one of two primary endpoints by reducing refractory angina in the ORBITA-COSMIC trial, but not the second, improvement in perfusion.
Source: medscape.com
Ntianginal Agents News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ntianginal Agents. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ntianginal Agents Today - Breaking & Trending Today
Angioplasty Finally Proven Beneficial in Stable Angina
The randomized ORBITA-2 trial, unlike the preceding ORBITA trial, shows benefit for percutaneous coronary intervention in patients with stable angina.
Source: medscape.com
Angioplasty Finally Proven Beneficial in Stable Angina
The randomized ORBITA-2 trial, unlike the preceding ORBITA trial, shows benefit for percutaneous coronary intervention in patients with stable angina.
Source: medscape.com